OncoTargets and Therapy is a peer-reviewed medical journal covering research on all aspects of oncology. The journal was established in 2008 and is published...
1 KB (84 words) - 13:06, 12 September 2024
Osteoporosis (redirect from Diet and bone health)
different types of breast cancer using support vector machine". OncoTargets and Therapy. 8: 2311–2317. doi:10.2147/OTT.S85271. ISSN 1178-6930. PMC 4556031...
143 KB (16,154 words) - 21:46, 29 May 2025
Experimental cancer treatment (redirect from Experimental cancer therapy)
hedgehog pathway for the treatment of cancer using Itraconazole". OncoTargets and Therapy. 12: 6875–6886. doi:10.2147/OTT.S223119. ISSN 1178-6930. PMC 6711563...
35 KB (4,222 words) - 04:18, 11 February 2025
signet-ring cell carcinoma: a report of two cases and review of the literature". OncoTargets and Therapy. 8: 91–97. doi:10.2147/OTT.S67921. PMC 4284042....
20 KB (2,270 words) - 13:39, 28 October 2024
List of Dove Medical Press academic journals (redirect from Blood and Lymphatic Cancer: Targets and Therapy)
Neuroeconomics† Nursing: Research and Reviews Nutrition and Dietary Supplements Oncolytic Virotherapy OncoTargets and Therapy Open Access Animal Physiology†...
7 KB (679 words) - 17:21, 28 February 2022
Solitary Fibrous Tumor in the Nasopharynx: Case Report and Literature Review". OncoTargets and Therapy. 13: 6819–6826. doi:10.2147/OTT.S252696. PMC 7367732...
2 KB (245 words) - 00:16, 31 August 2023
(2015-02-03). "The utility of bexarotene in mycosis fungoides and Sézary syndrome". OncoTargets and Therapy. 8: 367–373. doi:10.2147/OTT.S61308. PMC 4322887. PMID 25678803...
20 KB (2,073 words) - 22:04, 29 May 2025
Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations". OncoTargets and Therapy. 15: 53–66. doi:10.2147/OTT.S345878. PMC 8763255...
6 KB (486 words) - 16:05, 19 September 2024
hedgehog pathway for the treatment of cancer using Itraconazole". OncoTargets and Therapy. 12: 6875–6886. doi:10.2147/OTT.S223119. PMC 6711563. PMID 31692536...
27 KB (2,483 words) - 21:13, 29 May 2025
Zanubrutinib (section Society and culture)
of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date". OncoTargets and Therapy. 13: 6573–6581. doi:10.2147/OTT.S238832. PMC 7351990. PMID 32753893...
24 KB (1,799 words) - 22:36, 29 May 2025
Sonophoresis (section Topical gene therapy)
Cisplatin in the Xenografted Tumor Model of Cervical Cancer". OncoTargets and Therapy. 13: 889–902. doi:10.2147/OTT.S238126. PMC 6996214. PMID 32099393...
27 KB (3,160 words) - 18:55, 23 May 2025
"Gemcitabine for the treatment of advanced nonsmall cell lung cancer". OncoTargets and Therapy. 2: 209–217. doi:10.2147/ott.s4645. PMC 2886326. PMID 20616908...
162 KB (14,924 words) - 20:42, 29 May 2025
Ovarian germ cell tumors (section Signs and Symptoms)
immature teratoma, yolk sac tumor and embryonal carcinoma harboring an EGFR mutation: a case report". OncoTargets and Therapy. 11: 6853–6862. doi:10.2147/ott...
28 KB (3,007 words) - 18:27, 10 February 2025
Indolent lymphoma (section Signs and symptoms)
on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date". OncoTargets and Therapy. 11: 4817–4827...
24 KB (2,687 words) - 14:05, 26 May 2025
Tamoxifen (section Cardiovascular and metabolic)
breast cancer: overview of clinical use and molecular biomarkers for patient selection". OncoTargets and Therapy. 4: 1–11. doi:10.2147/OTT.S10155. PMC 3084302...
88 KB (9,262 words) - 00:51, 17 February 2025
Pembrolizumab (category Wikipedia articles incorporating text from the United States Department of Health and Human Services)
pembrolizumab in non-small cell lung cancer: the evidence to date". OncoTargets and Therapy. 9: 5855–5866. doi:10.2147/ott.s97746. PMC 5045223. PMID 27713639...
83 KB (7,695 words) - 21:50, 29 May 2025
of ovarian cancer cells by regulating mitochondrial function". OncoTargets and Therapy. 12: 1729–1739. doi:10.2147/ott.s194329. PMC 6419601. PMID 30881027...
22 KB (1,954 words) - 13:35, 24 May 2025
therapy for insomnia (CBT-I) is a therapy technique for treating insomnia without (or alongside) medications. CBT-I aims to improve sleep habits and behaviors...
39 KB (4,621 words) - 04:56, 2 June 2025
Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002. OncoTargets and therapy. 2015;8:877. Han JB, Sang F, Chang JJ...
27 KB (3,866 words) - 22:30, 24 May 2025
CAR T cell (redirect from CAR T-cell therapy)
lentivirus such as HIV (see Lentiviral vector in gene therapy). The CAR programs the T cells to target an antigen present on the tumor cell surface. For safety...
92 KB (9,308 words) - 20:16, 29 May 2025
NORAD in colorectal cancer associates with tumor progression". OncoTargets and Therapy. 11: 6757–6766. doi:10.2147/OTT.S176354. PMC 6188072. PMID 30349308...
11 KB (1,276 words) - 03:05, 27 May 2025
BCL3 (section Role in cancer therapy)
oncogenic function by regulating STAT3 in human cervical cancer". OncoTargets and Therapy. 9: 6619–6629. doi:10.2147/OTT.S118184. PMC 5087794. PMID 27822067...
23 KB (2,553 words) - 23:08, 3 August 2024
AIDS-related lymphoma (section Signs and symptoms)
Chaitra (2018). "Primary effusion lymphoma: current perspectives". OncoTargets and Therapy. 11. Informa UK Limited: 3747–3754. doi:10.2147/ott.s167392. ISSN 1178-6930...
24 KB (2,336 words) - 14:07, 16 November 2024
MDA-MB231 (section History and characteristics)
Triple-Negative Breast Cancer MDA-MB-231 Cell Spheroid Model". OncoTargets and Therapy. 13: 5395–5405. doi:10.2147/OTT.S249756. PMC 7295545. PMID 32606757...
8 KB (936 words) - 20:17, 20 January 2025
P53 (section DNA damage and repair)
splice variants in human malignancy: a clinical perspective". OncoTargets and Therapy. 7: 57–68. doi:10.2147/OTT.S53876. PMC 3872270. PMID 24379683....
131 KB (14,418 words) - 05:49, 1 June 2025
Talimogene laherparepvec (redirect from OncoVEX GM-CSF)
"A practical guide to the handling and administration of talimogene laherparepvec in Europe". OncoTargets and Therapy. 10: 3867–3880. doi:10.2147/OTT.S133699...
20 KB (1,900 words) - 22:18, 29 May 2025
of myelodysplastic syndromes: clinical utility of azacitidine". OncoTargets and Therapy. 3: 157–65. doi:10.2147/OTT.S5852. PMC 2939768. PMID 20856790....
25 KB (2,930 words) - 20:21, 29 May 2025
2016). "PD-L1 expression in human cancers and its association with clinical outcomes". OncoTargets and Therapy. 9: 5023–39. doi:10.2147/OTT.S105862. PMC 4990391...
39 KB (5,003 words) - 21:58, 29 May 2025
Sadek I (2016-09-08). "Sunitinib: the antiangiogenic effects and beyond". OncoTargets and Therapy. 9: 5495–505. doi:10.2147/OTT.S112242. PMC 5021055. PMID 27660467...
46 KB (4,900 words) - 21:27, 29 May 2025
"Non-secretory multiple myeloma: from biology to clinical management". OncoTargets and Therapy. 9: 7583–7590. doi:10.2147/OTT.S122241. PMC 5171196. PMID 28008276...
81 KB (10,828 words) - 14:01, 6 February 2025